natgillin/translations-raw huggingface dataset:
Keep the blister in the outer carton in order to protect from light. 
Pretisni omot shranjujte v zunanji ovojnini za zagotovitev zaščite pred svetlobo.
Loperamide was administered to 13% of patients in 5% of courses. 
Loperamid je dobilo 13 % bolnikov v 5 % ciklusov.
Initial dose The recommended dose of HYCAMTIN capsules is 2.3 mg/m body surface area per day administered for five consecutive days with a three-week interval between the start of each course. 
Priporočeni odmerek kapsul HYCAMTIN je 2,3 mg/m telesne površine na dan pet dni zapored in s tritedenskimi presledki med začetki posameznih ciklusov zdravljenja.
WARNING: Cytotoxic agent, special handling instructions (see Package Leaflet). 
OPOZORILO: citotoksično zdravilo, posebna navodila za ravnanje (glejte Navodilo za uporabo).
Reconstitute before use. 
za intravensko uporabo Pred uporabo rekonstituirajte.
In this study, forty-six (43%) patients received G-CSF over 192 (42.1%) courses; sixty-five (60%) received transfusions of packed red blood cells and fifty (46%) of platelets over 139 and 159 courses (30.5% and 34.9%), respectively. 
V tej študiji je šestinštirideset (43 %) bolnikov v 192 ciklusih (42,1 %) prejelo G-CSF, petinšestdeset (60 %) bolnikov je v 139 ciklusih (30,5 %) prejelo transfuzijo koncentriranih eritrocitov, petdeset (46 %) bolnikov pa v 159 ciklusih (34,9 %) transfuzijo trombocitov.
topotecan was discontinued if the dose had been reduced to 1.0 mg/m 2/day and a further dose reduction was required to manage adverse effects. 
V kliničnih študijah so topotekan prenehali uporabljati, če je bil odmerek že zmanjšan na 1,0 mg/m 2/dan in bi ga bilo treba zaradi neželenih učinkov še dodatno zmanjšati.
• If you get any side effects, talk to your doctor. 
• Če opazite kateri koli neželeni učinek, se posvetujte z zdravnikom.
9/l) occurred in 6% of patients in 2% of courses. 
9/l) se je pojavila pri 6 % bolnikov v 2 % ciklusov.
Titanium dioxide (E171) 
Ovojnica kapsule želatina titanov dioksid (E171)
Overall, the N-desmethyl metabolite contributed a mean of less than 7% (range 4-9%) of the total topotecan-related material accounted for in the urine and faeces. 
Presnovek N-desmetil predstavlja v povprečju manj kot 7 % (od 4 do 9 %) vseh s topotekanom povezanih snovi prisotnih v urinu in blatu.
Additional adverse events were seen when topotecan was given in combination with cisplatin; however, these events were seen with cisplatin monotherapy and were not attributable to topotecan. 
Pri dajanju topotekana v kombinaciji s cisplatinom so opazili dodatne neželene učinke, vendar pa so te neželene učinke opažali tudi pri samostojnem zdravljenju s cisplatinom in jih ni mogoče pripisati topotekanu.
Tumour types included were Ewing's sarcoma/primitive neuroectodermal tumour, neuroblastoma, osteoblastoma and rhabdomyosarcoma. 
Vključene so bile naslednje vrste tumorjev: Ewingov sarkom/primitivni nevroektodermalni tumor, nevroblastom, osteoblastom in rabdomiosarkom.
In 46% of courses with moderate to severe anaemia, the duration was >7 days. 
V 46 % ciklusov z zmerno do hudo anemijo je ta trajala >7 dni.
Overall, the Ndesmethyl metabolite contributed a mean of less than 6% (range 4-8%) of the total topotecan-related material accounted for in the urine and faeces. 
V celoti je predstavljal N-desmetilni presnovek povprečno manj kot 6 % (od 4 do 8 %) vseh s topotekanom povezanih snovi v urinu in blatu.
The contents of HYCAMTIN 4 mg vials must be reconstituted with 4 ml water for injections. 
Vsebino viale z zdravilom HYCAMTIN 4 mg je treba rekonstituirati s 4 ml vode za injekcije.
Storage of the prepared solution 
Shranjevanje pripravljene raztopine
Rarely, it can lead to more severe bleeding (haemorrhage). 
V redkih primerih lahko pride tudi do hujših krvavitev.
Patients with prior exposure to cisplatin require a sustained treatment-free interval to justify treatment with the combination (see section 5.1). 
Pri bolnicah, ki so se predhodno zdravile s cisplatinom, mora preteči daljše obdobje brez zdravljenja, da bi bilo zdravljenje s kombinacijo smiselno (glejte poglavje 5.1).
Median overall survival was 62 weeks for topotecan versus 53 weeks for paclitaxel (hazard ratio 0.9 [0.6, 1.3]). 
Mediana časa celokupnega preživetja je bila 62 tednov pri uporabi topotekana in 53 tednov pri zdravljenju s paklitakselom (razmerje ogroženosti 0,9 0,6, 1,3).
A small number of hepatically impaired patients (serum bilirubin between 1.5 and 10 mg/dl) were given intravenous topotecan at 1.5 mg/m2/day for five days every three weeks. 
Manjšemu številu bolnikov z jetrno okvaro (z vrednostmi bilirubina v serumu med 1,5 in 10 mg/dl) so intravensko dajali odmerke topotekana 1,5 mg/m2/dan po pet dni na vsake tri tedne.
In the oral topotecan plus BSC group there was a statistically significant improvement in overall survival compared with the BSC alone group (Log-rank p = 0.0104). 
Celotno preživetje v skupini, ki je dobivala peroralni topotekan in NPO, je bilo statistično značilno boljše kot v skupini, ki je bila deležna le NPO (vrednost p za log-rang = 0,0104).
Contact a doctor or pharmacist immediately for advice if you have taken too many capsules or if a child has accidentally taken the medicine. 
Če ste vzeli večji odmerek zdravila Hycamtin, kot bi smeli Če ste vzeli preveč kapsul ali če je otrok po nesreči vzel vaše zdravilo, se nemudoma posvetujte z zdravnikom ali farmacevtom.
• Inflammation and ulcers of the mouth tongue or gums. 
• vnetje in razjede na jeziku ali dlesnih;
Overdoses have been reported in patients being treated with topotecan capsules (up to 5 fold of the recommended dose) and intravenous topotecan (up to 10 fold of the recommended dose). 
O prevelikem odmerjanju so poročali pri bolnikih, ki so prejemali topotekan v kapsulah (do 5-kratni priporočeni odmerek) in topotekan intravensko (do 10-kratni priporočeni odmerek).
Following co-administration of the ABCB1 (P-gp) and ABCG2 (BCRP) inhibitor, elacridar (GF120918) at 100 to 1000 mg with oral topotecan, the AUC0-∞ of topotecan lactone and total topotecan increased approximately 2.5-fold (see section 4.5 for guidance). 
Po sočasni uporabi elakridarja (GF120918) (zaviralca ABCB1 (P-gp) in ABCG2 (BCRP)) v odmerku 100 in 1.000 mg skupaj s peroralnim topotekanom sta se AUC0-∞ topotekanovega laktona in celotnega topotekana povečali približno 2,5-krat (glejte poglavje 4.5 za pojasnila).
• Occasionally severe stomach pain, fever and possibly diarrhoea (rarely with blood) can be signs of bowel inflammation (colitis). 
• Občasne hude bolečine v želodcu, zvišana telesna temperatura, lahko tudi driska (redko krvava) so lahko znaki vnetja črevesja (kolitisa).
Signs include: difficulty breathing cough fever. 
Med znaki so: težko dihanje, kašelj, zvišana telesna temperatura.
The frequencies associated with the haematological and non-haematological adverse events presented are for adverse events considered to be related/possibly related to oral topotecan therapy. 
V nadaljevanju navedene pogostnosti hematoloških in nehematoloških neželenih učinkov veljajo za učinke, ki so povezani ali so morda povezani s peroralno uporabo topotekana.
The recommended dose of topotecan is 1.5 mg/m body surface area per day administered by intravenous infusion over 30 minutes daily for five consecutive days with a three-week interval between the start of each course. 
Priporočeni odmerek topotekana je 1,5 mg/m telesne površine na dan z intravensko infuzijo, ki traja po 30 minut dnevno, v ciklusih po pet zaporednih dni in s tritedenskimi presledki med začetki posameznih ciklusov zdravljenja.
9/l) during course 1 in 55% of patients, with duration  seven days in 20%, and overall in 77% of patients (39% of courses). 
9/l), ki je pri 20 % bolnikov trajala najmanj sedem dni, med celotnim obdobjem zdravljenja pa se je huda nevtropenija pojavila pri 77 % bolnikov (v 39 % ciklusov zdravljenja).
What you need to know before you are given Hycamtin 
Kaj morate vedeti, preden boste prejeli zdravilo Hycamtin
Accidental contact with the skin or eyes should be treated immediately with copious amounts of water. 
- Ob nehotenem stiku zdravila s kožo ali z očmi jih je treba takoj sprati z veliko količino vode.
9/l) occurred in 29% of patients in 14% of courses. 
9/l) se je pojavila pri 29 % bolnikov v 14 % ciklusov.
Fatigue was observed in approximately 25% and asthenia in 16% of patients receiving topotecan. 
Pri bolnikih, ki so prejemali topotekan, so v približno 25 % opazili utrujenost, v 16 % pa astenijo.
There are insufficient data available with HYCAMTIN capsules to make a dose recommendation for this patient group (see section 4.4). 
Za kapsule HYCAMTIN ni dovolj podatkov, da bi lahko oblikovali priporočila za odmerjanje v tej skupini bolnikov (glejte poglavje 4.4).
Overdoses have been reported in patients being treated with intravenous topotecan (up to 10 fold of the recommended dose) and topotecan capsules (up to 5 fold of the recommended dose). 
O prevelikem odmerjanju so poročali pri bolnikih, ki so prejemali topotekan intravensko (do 10-kratni priporočeni odmerek) in topotekan v kapsulah (do 5-kratni priporočeni odmerek).
Geometric mean topotecan lactone dose-normalised AUC(0-) values for Korean patients were 7.9, 12.9 and 19.7 ng*h/ml in subjects with creatinine clearance values of more than 80 ml/min, 50 to 80 ml/min and 30 to 49 ml/min, respectively (see section 4.2 and 4.4). 
Pri korejskih bolnikih so bile geometrične srednje vrednosti AUC(0-) za topotekan lakton, normalizirane glede na odmerek, 7,9, 12,9 oziroma 19,7 ng*h/ml pri posameznikih z očistkom kreatinina >80 ml/min, 50-80 ml/min oziroma 30-49 ml/min (glejte poglavji 4.2 in 4.4).
Pregnant staff should be excluded from working with this medicinal product. 
- Pri rokovanju z zdravilom ne smejo sodelovati nosečnice.
The clear, reconstituted solution is yellow to yellow-green in colour and provides 1 mg of topotecan per ml. 
Pripravljena bistra raztopina je rumene do rumeno-zelene barve in vsebuje 1 mg topotekana na mililiter.
The recommended monotherapy dose of topotecan in patients with ovarian or small cell lung carcinoma and a creatinine clearance between 20 and 39 ml/min is 0.75 mg/m2/day for five consecutive days. 
Priporočeni odmerek topotekana kot samostojnega zdravila pri zdravljenju bolnic s karcinomom jajčnika in bolnikov z drobnoceličnim pljučnim karcinomom, ki imajo očistek kreatinina med 20 in 39 ml/min, je 0,75 mg/m2/dan, pet zaporednih dni.
Severe (Grade 3 or 4) fatigue and asthenia both occurred with an incidence of 3%. 
Huda oblika (3. ali 4. stopnje) tako utrujenosti kot astenije se je pojavljala s pogostnostjo 3 %.
The second study included a dose range of 2.0 to 5.2 mg/m in children (n = 8), adolescents (n = 3) and young adults (n = 3) with leukaemia. 
V drugi študiji so otroci (n = 8), mladostniki (n = 3) in mlajši odrasli (n = 3) z levkemijo prejemali odmerek od 2,0 do 5,2 mg/m2.
The pharmacokinetics of topotecan were generally unchanged when co-administered with ranitidine. 
Farmakokinetika topotekana se med sočasno uporabo z ranitidinom na splošno ni spremenila.
What Hycamtin is and what it is used for What you need to know before you are given Hycamtin How Hycamtin is used 
Kaj je zdravilo Hycamtin in za kaj ga uporabljamo Kaj morate vedeti, preden boste prejeli zdravilo Hycamtin Kako uporabljati zdravilo Hycamtin Možni neželeni učinki
Cyclosporin A (an inhibitor of ABCB1, ABCC1 [MRP-1], and CYP3A4) administered with oral topotecan increased topotecan AUC to approximately 2-2.5-fold of control. 
Hkrati s peroralnim topotekanom uporabljeni ciklosporin A (ki zavira ABCB1, ABCC1 [MRP-1] in CYP3A4) je povečal AUC topotekana na približno 2 - 2,5-kratno vrednost v primerjavi s kontrolno skupino.
Median time to onset of severe neutropenia was nine days and the median duration was seven days. 
Mediana časa do začetka hude nevtropenije je bila devet dni, mediana trajanja nevtropenije pa sedem dni.
Platelet transfusions were given to 10% of patients in 4% of courses. 
Transfuzije trombocitov je dobilo 10 % bolnikov v 4 % ciklusov.
Hycamtin 1 mg capsules are pink and imprinted with “Hycamtin” and “1 mg”. 
1-miligramske kapsule Hycamtin so rožnate barve in označene s ‘Hycamtin' in ‘1 mg'.
Geometric mean topotecan lactone dose-normalised AUC(0-) values were 9.4, 11.1 and 12.0 ng*h/ml in subjects with creatinine clearance values of more than 80 ml/min, 50 to 80 ml/min and 30 to 49 ml/min, respectively. 
Geometrične srednje vrednosti AUC(0) za topotekan lakton, normalizirane glede na odmerek, so bile 9,4, 11,1 oziroma 12,0 ng*h/ml pri posameznikih z očistkom kreatinina >80 ml/min, 50 - 80 ml/min oziroma 30 - 49 ml/min.
Administration of oral cyclosporine A (15 mg/kg), an inhibitor of transporters ABCB1 (P-gp) and ABCC1 (MRP-1) as well as the metabolising enzyme CYP3A4, within 4 hours of oral topotecan increased the dose normalised AUC0-24h of topotecan lactone and total topotecan approximately 2.0and 2.5-fold, respectively (see section 4.5). 
Peroralno uporabljeni ciklosporin A (15 mg/kg), zaviralec transportnih beljakovin ABCB1 (P-gp) in ABCC1 (MRP-1) ter presnovnega encima CYP3A4, je v 4 urah po peroralnem odmerjanju topotekana povečal za odmerek normalizirano AUC0-24h topotekanovega laktona za približno 2,0-krat in celotnega topotekana za približno 2,5-krat (glejte poglavje 4.5).
Haematological 
Hematološki
Sealing band Gelatin 
Zaporni trak želatina
No effects on male or female fertility have been observed in reproductive toxicity studies in rats (see section 5.3). 
V študijah vpliva na sposobnost razmnoževanja pri podganah niso ugotovili učinkov na plodnost samcev ali samic (glejte poglavje 5.3).
What you need to know before you take Hycamtin 
Kaj morate vedeti, preden boste vzeli zdravilo Hycamtin
Light yellow to greenish powder. 
prašek za koncentrat za raztopino za infundiranje Svetlo rumen do zelenkast prašek.
Median (95% CI) Hazard ratio (95% CI) 
Mediana vrednost (95-odstotni IZ) Razmerje tveganja (95-odstotni IZ)
Erythropoietin was administered to 10% of patients in 8% of courses. 
Eritropoetin je dobilo 10 % bolnikov v 8 % ciklusov.
Topotecan has been associated with reports of interstitial lung disease (ILD), some of which have been fatal (see section 4.8). 
Med uporabo topotekana so bili opisani primeri intersticijske bolezni pljuč (IBP), nekateri s smrtnim izidom (glejte poglavje 4.8).
Neutropenic colitis, including fatal neutropenic colitis, has been reported to occur as a complication of topotecan-induced neutropenia (see section 4.4). 
O nevtropeničnem kolitisu, vključno z nevtropeničnim kolitisom s smrtnim izidom, so poročali kot o zapletu s topotekanom povzročene nevtropenije (glejte poglavje 4.4).
Red cell transfusions were given in 52% of patients (21% of courses). 
52 % bolnikov je prejelo transfuzijo eritrocitov (v 21 % ciklusov zdravljenja).
The capsules are opaque, pink and imprinted with “HYCAMTIN” and “1 mg”. 
Kapsule so neprosojne, rožnate barve in označene s ‘HYCAMTIN' in ‘1 mg'.
The overall haematological toxicity is lower in patients treated with topotecan in combination with cisplatin compared to topotecan monotherapy, but higher than with cisplatin alone. 
Pri bolnikih, ki so se zdravili s topotekanom v kombinaciji s cisplatinom, je bila celotna hematološka toksičnost manjša kot pri samostojnem zdravljenju s topotekanom, vendar večja kot pri samostojnem zdravljenju s cisplatinom.
Neutropenia Severe neutropenia (Grade 4 - neutrophil count <0.5 x 10 
Nevtropenija Huda nevtropenija (4. stopnje - število nevtrofilcev <0,5 x 10
Each capsule contains topotecan hydrochloride equivalent to 1 mg of topotecan. 
Ena kapsula vsebuje topotekanijev klorid, ki ustreza 1 mg topotekana.
The frequencies associated with the haematological and non-haematological adverse events listed below represent the adverse event reports considered to be related/possibly related to topotecan therapy. 
V nadaljevanju navedena pogostnost hematoloških in nehematoloških neželenih dogodkov se nanaša na poročila o neželenih dogodkih, ki so bili ali bi lahko bili povezani z zdravljenjem s topotekanom.
What Hycamtin contains 
Kaj vsebuje zdravilo Hycamtin
The cellular sequela of inhibition of topoisomerase-I by topotecan is the induction of protein-associated DNA single-strand breaks. 
Celična posledica zaviranja topoizomeraze I s topotekanom je nastanek prekinitev na enojni verigi DNA, vezani na beljakovino.
9/l and/or a platelet count of 100 x 10 
9/l in/ali števila trombocitov 100 x 10
In clinical studies involving patients with relapsed small cell lung cancer, the dose-limiting toxicity of oral topotecan monotherapy was found to be haematological. 
V kliničnih študijah pri bolnikih s ponovitvijo drobnoceličnega pljučnega raka so ugotovili, da pri zdravljenju s peroralnim topotekanom kot samostojnim zdravilom, odmerek omejuje hematološka toksičnost.
Consult your doctor after eye contact or if you experience a skin reaction. 
Če je zdravilo prišlo v oko ali če se vam pojavi reakcija na koži, se posvetujte z zdravnikom.
Oral topotecan Intravenous topotecan 
peroralni topotekan intravenski topotekan peroralni topotekan intravenski topotekan
Medicinal product subject to restricted medical prescription (See Annex I: Summary of Product Characteristics, section 4.2). 
Predpisovanji in izdaja zdravila je le na recept s posebnim režimom (glejte Prilogo I: Povzetek glavnih značilnosti zdravila, poglavje 4.2).
The integrated safety data for topotecan monotherapy are presented below. 
V nadaljevanju je naveden povzetek podatkov o varnosti topotekana kot samostojnega zdravila.
The capsules are opaque, white to yellowish white and imprinted with “HYCAMTIN” and “0.25 mg”. 
Kapsule so neprosojne, bele do rumenkasto bele barve in označene s ‘HYCAMTIN' in ‘0.25 mg'.
If dose reduction is chosen for patients who experience severe neutropenia (neutrophil count <0.5 x 10 
Pri odločitvi za zmanjšanje odmerka pri bolnikih s hudo nevtropenijo (število nevtrofilcev <0,5 x 10
9/l) for seven days or more or severe neutropenia associated with fever or infection, or who have had treatment delayed due to neutropenia, the dose should be reduced by 20% to 0.60 mg/m 2/day for subsequent courses (or subsequently down to 0.45 mg/m 2/day if necessary). 
9/l), ki traja sedem ali več dni, ali s hudo nevtropenijo z zvišano telesno temperaturo ali okužbo ali pri bolnicah, ki jim je bilo treba zdravljenje odložiti zaradi nevtropenije, je treba odmerek pri naslednjih ciklusih zmanjšati za 20 % na 0,60 mg/m 2/dan (ali ga po potrebi kasneje še dodatno zmanjšati na 0,45 mg/m 2/dan).
In association with severe neutropenia, fever or infection occurred in 16% of patients during course 1 and overall in 23% of patients (6% of courses). 
Ob hudi nevtropeniji so med prvim ciklusom zdravljenja pri 16 % bolnikov opazili zvišano telesno temperaturo ali okužbo, med celotnim obdobjem zdravljenja pa je imelo take neželene učinke 23 % bolnikov (v 6 % ciklusov zdravljenja).
Toxicities of topotecan in paediatric patients with recurrent and refractory solid tumours were similar to those historically seen in adult patients. 
Pri otrocih z rekurentnimi in neodzivnimi solidnimi tumorji je bila toksičnost topotekana podobna toksičnosti, ki so jo že prej opažali pri odraslih bolnikih.
Each capsule contains topotecan hydrochloride equivalent to 0.25 mg of topotecan. 
Ena kapsula vsebuje topotekanijev klorid, ki ustreza 0,25 mg topotekana.
Patients should be monitored for pulmonary symptoms indicative of ILD (e.g. cough, fever, dyspnoea and/or hypoxia), and topotecan should be discontinued if a new diagnosis of ILD is confirmed. 
Bolnike je treba kontrolirati glede pljučnih simptomov, ki kažejo na IBP (npr. kašelj, zvišana telesna temperatura, dispneja in/ali hipoksija).
If reconstitution and dilution are performed under strict aseptic conditions (e.g. an LAF bench) the product should be used (infusion completed) within 24 hours if stored at 2ºC - 8ºC after the first puncture of the vial. 
Če priprava in redčenje potekata v strogo aseptičnih pogojih, na primer v napravi z laminarnim tokom zraka (LAF), je treba zdravilo porabiti (dokončati infuzijo) v 24 urah, če ga takoj po prvem odprtju viale hranimo pri temperaturi od 2 °C do 8 °C.
Red blood cell transfusions were given in 30% of patients (13% of courses). 
Transfuzije eritrocitov je dobilo 30 % bolnikov (v 13 % ciklusov).
If cisplatin is discontinued, there are insufficient data regarding continuing monotherapy with topotecan in patients with cervical cancer. 
Če se pri bolnicah z rakom materničnega vratu zdravljenje s cisplatinom ukine, za nadaljevanje zdravljenja samo s topotekanom ni zadostnih podatkov.
MARKETING AUTHORISATION NUMBERS 
ŠTEVILKE DOVOLJENJ ZA PROMET Z ZDRAVILOM
Very common Nausea, vomiting and diarrhoea (all of which may be severe), constipation, 
Bolezni prebavil zelo pogosti navzea, bruhanje in driska (vse lahko v hudi obliki), zaprtje, bolečine v trebuhu
What Hycamtin is and what it is used for What you need to know before you take Hycamtin How to take Hycamtin 
Kaj je zdravilo Hycamtin in za kaj ga uporabljamo Kaj morate vedeti, preden boste vzeli zdravilo Hycamtin Kako jemati zdravilo Hycamtin Možni neželeni učinki
The primary complications of overdose are bone marrow suppression and mucositis. 
Primarna zapleta prevelikega odmerjanja sta supresija kostnega mozga in vnetje ustne sluznice.
A major route of clearance of topotecan is by hydrolysis of the lactone ring to form the ring-opened carboxylate. 
Glavna pot razgradnje topotekana je hidroliza laktonskega obroča, s katero nastane karboksilat z odprtim obročem.
Median survival in patients treated with oral topotecan plus BSC was 25.9 weeks (95% CI: 18.3, 31.6) compared to 13.9 weeks (95% CI: 11.1, 18.6) for patients receiving BSC alone (p = 0.0104). 
Mediana časa preživetja bolnikov, ki so bili zdravljeni s peroralnim topotekanom v kombinaciji z NPO, je bila 25,9 tedna (95-odstotni IZ: 18,3, 31,6), pri bolnikih, ki so bili zdravljeni z NPO samo, pa 13,9 tedna (95-odstotni IZ: 11,1, 18,6) (p = 0,0104).
HYCAMTIN 4 mg is available in packs containing 1 vial and 5 vials. 
Zdravilo HYCAMTIN 4 mg je na voljo v pakiranjih z 1 vialo ali 5 vialami.
Also contains: tartaric acid (E334), mannitol (E421), hydrochloric acid (E507), sodium hydroxide. 
Vsebuje tudi: vinsko kislino (E334), manitol (E421), klorovodikovo kislino (E507) in natrijev hidroksid.
However, there are insufficient data available to make a dose recommendation for this patient group. 
Pri tem so opažali zmanjšan očistek topotekana, vendar ni na voljo dovolj podatkov, da bi lahko oblikovali priporočila za odmerjanje za to skupino bolnikov.
Hycamtin capsules must not be opened or crushed. 
Kapsul HYCAMTIN se ne sme odpirati ali drobiti.
Topotecan plus cisplatin had a statistically significant benefit in overall survival relative to cisplatin monotherapy after adjusting for interim analyses (Log-rank p = 0.033). 
Po prilagajanju na vmesno analizo je kombinacija topotekana in cisplatina dosegla statistično značilno boljše celokupno preživetje v primerjavi z zdravljenjem s samim cisplatinom (log-rank p = 0,033).
Patients should be carefully monitored for adverse reactions when oral topotecan is administered with a substance known to inhibit ABCB1 or ABCG2 (see section 5.2). 
Pri sočasni uporabi peroralnega topotekana s katero od učinkovin, ki zavira ABCB1 ali ABCG2, je treba bolnike natančno spremljati glede neželenih učinkov (glejte poglavje 5.2).
Further dilution of the appropriate volume of the reconstituted solution with either sodium chloride 9 mg/ml (0.9%) or 5% w/v glucose is required to give a final concentration of between 25 and 50 microgram/ml. 
Ustrezno količino tako pripravljene raztopine je treba še dodatno razredčiti bodisi z 0,9-odstotno raztopino natrijevega klorida (9 mg/ml) ali s 5-odstotno (m/v) raztopino glukoze, da nastane končni pripravek s koncentracijo med 25 in 50 mikrogramov/ml.
Median time to onset of severe thrombocytopenia was day 15 and the median duration was five days. 
Mediana časa do pojava hude trombocitopenije je bila 15. dan, mediana trajanja trombocitopenije pa pet dni.